The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D

Zaigham Abbas, Muhammad Saad, Muhammad Asim, Minaam Abbas, Shoukat Ali Samejo

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background/Aims: Sodium taurocholate co-transporting polypeptide (NTCP) is the receptor for the hepatitis B virus (HBV) and hepatitis D virus (HDV) entry into hepatocytes. Ezetimibe is a cholesterol-lowering drug that possesses the pharmacophore features to inhibit NTCP. This study evaluates the efficacy of ezetimibe in patients with chronic HDV infection in a nonrandomized trial. Materials and Methods: This proof of concept phase 2 trial evaluated the efficacy and safety of ezetimibe 10 mg daily in (interferon treatment-experienced or interferon ineligible) patients with chronic hepatitis D (CHD). Forty-four patients with CHD were recruited, 38 male and 6 female patients, mean age 35.2±8.7 (range 19-64). Fifteen (34%) patients were on concomitant nucleoside therapy, and cirrhosis was present in 14 subjects. The primary therapeutic endpoint was a decline in HDV RNA at one log or more from the baseline at week 12. Results: The mean HDV RNA level was 5.4±1.3 log10 IU/mL. HBeAg was non-reactive in 43 (98%). HBV DNA was undetectable in 28 (64%). One patient stopped treatment at week 4, and one patient did not follow-up. One log or more reduction in the HDV RNA levels was observed in 18/44 (41%) patients. No log reduction occurred in 16 patients, and 8 experienced a log increase. No adverse effects from the concomitant nucleoside analogue use or clinical cirrhosis were observed. The drug exhibited a positive safety profile. Conclusion: Treatment of CHD patients with ezetimibe resulted in a one log reduction of viral load in 43% (18/42) of the patients who completed the 12 weeks of therapy.

Original languageEnglish
Pages (from-to)136-141
Number of pages6
JournalTurkish Journal of Gastroenterology
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2020
Externally publishedYes

Keywords

  • Ezetimibe
  • HDV RNA
  • Hepatitis D
  • Sodium taurocholate co-transporting polypeptide

Fingerprint

Dive into the research topics of 'The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D'. Together they form a unique fingerprint.

Cite this